This disclosure describes methods that allow for the uncoupling of microbial growth from product formation, which allows for maximal use of raw material and optimal end-product formation.

The disclosure provides methods for carrying out Real Time Cellular Thermal Shift Assays (RT-CETSA). Also provided are molecular constructs and protein constructs for use in such assays and devices suitable for carrying out such assays.

Provided is a microorganism that is able to produce 2-phenylethanol at a high concentration, and a method of efficiently producing 2-phenylethanol by using a saccharide as a raw material.

Provided is a coryneform bacterium transformant in which a shikimate pathway is activated, and further, a gene that encodes an enzyme having phenylpyruvate decarboxylase activity is introduced in such a manner that the gene can be expressed.

Also provided is a 2-phenylethanol producing method that includes causing the coryneform bacterium transformant according to the present disclosure to react in water containing a saccharide.

The invention discloses an alcohol dehydrogenase mutant and use thereof. The alcohol dehydrogenase mutant of the present invention has high thermal stability and enables high catalytic efficiency and high conversion rate (i.e. space time yield) in the asymmetric reduction of prochiral diaryl ketones to produce chiral diaryl alcohols. Therefore, the alcohol dehydrogenase mutant of the present invention has extremely high prospect of application in the production of chiral diaryl alcohols, such as (S)-(4-chlorophenyl)-(pyridin-2-yl)-methanol, (R)-(4-chlorophenyl)-(pyridin-2-yl)-methanol.

The present disclosure provides recombinant bacteria for production of D-lactate and/or L-lactate. Pharmaceutical compositions and methods of treating diseases are also included in the present invention.

Disclosed herein are genetically engineered hematopoietic cells, which express one or more lactate-modulating factors (e.g., polypeptides), and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.

An engineered bacterium for producing ethanol from one or more carbohydrates is disclosed. The bacterium can be made by (a) inactivating within a Lactobacillus casei bacterium one or more endogenous genes encoding a lactate dehydrogenase; or (b) introducing into a Lactobacillus casei bacterium one or more exogenous genes encoding a pyruvate decarboxylase and one or more exogenous genes encoding an alcohol dehydrogenase II; or (c) performing both steps (a) and (b). The resulting engineered bacterium produces significantly more ethanol than the wild-type Lactobacillus casei bacterium, and can be used in producing ethanol from a substrate such as biomass that includes carbohydrates.

The present invention relates to anticancer extracellular vesicles, a preparation method therefor, and an anticancer composition comprising same. Immune-tolerized extracellular vesicles containing LDHB and PGC-1α of the present invention provide cancer treatment, suppression of cancer metastasis, and cancer prevention technologies by normalizing cancer cell-specific aerobic glycolysis energy metabolic pathway in which lactate and hydrogen ions, which form a tumor microenvironment favorable for immune evasion, proliferation, metastasis and invasion of cancer cells, are produced, thereby enabling tumors to be effectively removed by means of the immune system of a patient.

The present invention relates to a novel promoter for regulating ADH gene expression in an organic acid-resistant yeast, and a method of producing an organic acid by expressing an organic acid production-related gene using the same. When an organic acid production-related target gene is expressed in the organic acid-resistant yeast using the novel promoter according to the present invention, there is an advantage in that the yeast can produce the organic acid with high efficiency while having resistance to the organic acid without inhibiting the growth ability of the yeast.

This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.